Takeda Gmbh

Torsten Dunkern

Beate Schmidt

Andreas Pahl

Josef Stadlwieser

Heiko Bernsmann

Ewald Benediktus

Ragna Hussong

Alexander Sudau

Degenhard Marx

Christof Zitt

Olaf Nimz

Matthias Mueller

Sarvesh S Patel

Thomas Maier

Dieter Flockerzi

Ulrich Kautz

Armin Hatzelmann

Hermann Tenor

Christian Hesslinger

Stefan Fischer

Steffen Weinbrenner

Raimund Külzer

Clemens Braun

Hiteshkumar D Jain

Rainer Boer

Thomas Stengel

Manojkumar Tiwari

Jörg Diefenbach

Harald Ohmer

Alexander Mann

Ashish Keche

Arati Prabhu

Sandip Gavade

Mahindra Makhija

Christiane Praechter

Simone Hartung

Manuela Hessmann

Angelika Hoffmeyer

The compounds of Formula (I), wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase and are useful for treating or preventing idiopathic pulmonary lung fibrosis.

Methylpyrrolopyrimidinecarboxamides

The compounds of formula (1) in which R1, R4, A and X have the meanings as given in the description, are novel effective EP2 agonists.

EP2 receptor agonists

The compounds of Formula (1), in which A, R1, R2, R3 and R5 have the meanings as given in the description, are novel effective inhibitors of type 4 and 5 phosphodiesterase.

3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives

The compounds of Formula (I), wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.

The compounds of Formula (I), wherein R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.

Methylpyrrolopyridinecarboxamides

The compounds of Formula (I), in which R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the N-oxides of the compounds and the salts thereof and the stereoisomers of the compounds, the salts, the N-oxides of the compounds and the N-oxides of the salts thereof are effective inhibitors of the type 5 phosphodiesterase.

Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines

Growing community of inventors

Juechen Gierath, Germany

Torsten Dunkern